Mia Elhidsi

Dr. Mia Elhidsi


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Verified
Journal Article
Open access
MEMia Elhidsi
Mia Elhidsi
MRMenaldi Rasmin
Menaldi Rasmin
PRPrasenohadi
Prasenohadi
Data on acute respiratory failure (ARF) in pulmonary tuberculosis (PTB) patients is limited. This study aims to investigate in-hospital mortality, its clinical risk factors and the accuracy of the existing scoring system in predicting in-hospital mortality. An observational prospective cohort study involving PTB patients with ARF in tertiary hospital, between January 2017 and December 2018, was conducted. The in-hospital mortality was predicted using the National Early Warning Score 2 (NEWS2), quick Sequential Organ Failure Assessment (qSOFA) and CRB-65. Regression models were run to analyze the clinical risk factors for in-hospital Mortality. Sensitivity and specificity of scoring systems were calculated using a Wilson score interval. A total of 111 subjects were included. Most of subjects were hypoxemic type respiratory failure (68.5%), advanced lesions (62.2%), new cases (70.3%) and pneumonia co-infection (72.1%) patients. Invasive mechanical ventilation was utilized for 29.73% of cases. There were 53 (47.75%) in-hospital mortality cases and its risk factors were intensive phase treatment (3.34 OR; CI95% 1.27–8.78), P/F ratio < 100 (OR 4.30; CI 95% 1.75–10.59) and renal insufficiency (4.09 OR; CI95% 1.46–11.49). The sensitivity and specificity of NEWS2 ≥ 6, qSOFA ≥ 2 and CRB-65 ≥ 2 were 62.26% and 67.24%; 60.38% and 72.41%; 41.51% and 84.48% respectively. Most of PTB with ARF were new cases, advanced lesion and hypoxemic type respiratory failure. Intensive phase treatment, severe hypoxemia and renal insufficiency are independent predictors of in-hospital mortality in PTB patients with ARF. NEWS2, qSOFA and CRB-65 scores were poor to predict the in-hospital mortality.

25 July 2022 in F1000Research
Verified
Journal Article
Open access
PDF file
MAMurdani Abdullah
Murdani Abdullah
JPJeanne Adiwinata Pawitan
Jeanne Adiwinata Pawitan
CICosphiadi Irawan
Cosphiadi Irawan
RARahyussalim
Rahyussalim
DADita Aditianingsih
Dita Aditianingsih
MEMia Elhidsi
Mia Elhidsi
Background: : Patients with severe COVID-19 had a higher increase in pro-inflammatory and anti-inflammatory cytokines than patients with moderate COVID-19. Excessive release of cytokine and chemokines can lead to multi-organ failure, increasing disease severity, length of stay, and mortality rate. Mesenchymal stem cells (MSCs) are known to have immunomodulatory, anti-inflammatory, anti-apoptotic, and angiogenesis effects that are useful for relieving inflammation, recovery, and protection of lung tissues in COVID-19 patients. Secretome, a secretory product of MSCs, has several advantages over MSCs. Therefore, we conducted a study to investigate secretomes’ effectiveness and safety profile as a treatment for severe COVID-19. Methods: This study was a double-blind, multicentered, randomized, placebo-controlled trial. This study involved 40 subjects recruited from three top COVID-19 referral hospitals in the Greater Jakarta area, Indonesia. Eligible subjects (n=40) were randomized in a 1:1 ratio to intervention group (n=20) and a control group (n=20). The primary outcome of this study was the improvement of inflammatory markers levels, measured by changes in inflammatory markers, and ratio of inflammatory to anti-inflammatory markers. The secondary outcomes of this study included clinical outcome, laboratory outcome, radiological outcome, RT-PCR result conversion, and safety profile of MSC secretome. Results: IL-6 marker in the control group was increased on the 14th day after the intervention compared to before intervention [4.110 (2.403–12.820) at baseline to 13.320 (2.958–33.285) on 14th day after intervention, p=0.017]. In the intervention group, there was no increase in the IL-6/IL-10 ratio. In contrast, in the control group, there was a significant increase in the IL-6/IL-10 ratio (p=0.036) on the 14th day after the intervention compared to before the intervention. We also found that on the seventh day after the intervention, most of the subjects who received placebo had high levels of IL-6 and ferritin (p=0.043). There was no significant difference in the laboratory outcome, radiological outcome, RT-PCR result conversion, and safety profile between both groups. Conclusions: Our study showed an increase of inflammation markers in the control group on the 14th day after the intervention, compared to the intervention group. The ratio of inflammatory to anti-inflammatory markers on the seventh and 14th days after intervention also did not increase in the intervention group. On the seventh day after intervention, most of the subjects in the control group also had high IL-6 levels and high ferritin levels. There is no adverse event reported. MSC secretome is a safe and promising treatment modality for severe COVID-19.

6 June 2024 in The Open Respiratory Medicine Journal
Verified
Journal Article
Open access
PDF file
MEMia Elhidsi
Mia Elhidsi
JZJamal Zaini
Jamal Zaini
LRLisnawati Rachmadi
Lisnawati Rachmadi
AAAsmarinah Asmarinah
Asmarinah Asmarinah
AKAria Kekalih
Aria Kekalih
MRMenaldi Rasmin
Menaldi Rasmin
Background: The location and type of a tumor influence the prognosis of lung cancer. Primary Central Lung Tumors (PCLTs) are correlated with poor prognoses and certain histologic types. This study aimed to present a comprehensive exploration of clinical and bronchoscopic assessments for diagnosing the histopathology types of PCLTs and identified the factors associated with certain histologic types. Methods: This was an observational cross-sectional study of PCLTs, defined as tumors in direct contact with hilar structures or located within the inner two-thirds of the hemithorax. We gathered demographic and clinical data, as well as data on bronchoscopy assessment and histopathology type. Tumor stage, symptoms of superior vena cava syndrome, and enlargement of lymph nodes in the paratracheal and subcarinal regions were also documented. Results: Of the 895 patients, 37.87% had primary lung tumors, with 17.76% classified as PCLTs. Notably, PCLT cases exhibited a higher proportion of stage III (28.9% vs. 18.3%; p = 0.03) and Squamous Cell Carcinoma (SCC) histopathology (37.1% vs. 17.2%; p = 0.00) compared with non-PCLT cases. Bronchoscopic findings in PCLTs revealed a predilection for central airway masses (25.2%) and compressive distal airway stenosis (25.2%). Subgroup analysis of 159 PCLT cases identified 37.10% as SCC. Multivariate analysis underscored that intraluminal masses predict central SCC (odds ratio 2.075, 95% confidence interval 1.07–3.99; p = 0.028). Conclusion: The proportion of stage III, SCC histopathological type, and intraluminal lesions was higher in patients with PCLT than in non-PCLT cases. The presence of intraluminal lesions can predict the histopathological type of SCC in patients with PCLTs.

20 June 2022 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
MEMia Elhidsi
Mia Elhidsi
JZJamal Zaini
Jamal Zaini
AGAziza Ghanie
Aziza Ghanie
AHAida Lutfi Huswatun
Aida Lutfi Huswatun
RBRomi Beginta
Romi Beginta
ESElisna Syahruddin
Elisna Syahruddin
Background: Adenoid cystic carcinoma of the lung is a distinctive salivary-gland-type malignant epithelial neoplasm that rarely presents as a primary tumor of the respiratory tract. Complete surgical resection remains the treatment of choice for adenoid cystic carcinoma. We present a case of large ACC tumors that caused severe central airway obstruction and were effectively treated with therapeutic bronchoscopy followed by radiotherapy and chemotherapy. Case presentation: A 31-year-old Malay Indonesian female patient who was a nonsmoker and had no family history of cancer was admitted to the emergency ward because of worsening breathlessness accompanied by stridor since 1 week prior. Chest computed tomography revealed segmental atelectasis of the left lung; a mass on the left main bronchus, with infiltrates in segments 1, 2, and 3 of the left lung; and consolidation in the left inferior lobe, with narrowing of the main left bronchus. Lobulated masses obstructing almost the entire distal trachea up to the carina and the entire left main bronchus were found on bronchoscopy. Owing to the large tumors causing severe central airway obstruction, the medical team decided to perform central airway mass removal through rigid bronchoscopy. A neodymium-doped yttrium-aluminum-garnet laser was used first to facilitate mass shrinkage. After the laser treatment, mechanical mass removal using a rigid scope was performed. The tracheal and carinal lumens were opened to > 50% of their diameter, with the left main bronchus lumen opened only slightly. After the treatment, the patient was stable, and no stridor was found. Adjuvant intensity-modulated radiotherapy and chemotherapy were performed after the therapeutic bronchoscopy. At the end of the entire treatment, reevaluation by thoracic computed tomography scan and bronchoscopy revealed no remaining mass. Conclusions: In cases of nonresectable large adenoid cystic carcinoma tumors with life-threatening central airway obstruction, therapeutic bronchoscopy followed by sequential radiochemotherapy might achieve a complete response outcome.

6 November 2022 in Case Reports in Pulmonology
Verified
Journal Article
Open access
PDF file
MEMia Elhidsi
Mia Elhidsi
DSDicky Soehardiman
Dicky Soehardiman
AWAgung Wibawanto
Agung Wibawanto
HMHaris Maruli
Haris Maruli
MAMaryastuti
Maryastuti
ESElisna Syahruddin
Elisna Syahruddin
Total airway obstruction in thyroid cancer is rare and has high morbidity and mortality. Airway management in such cases is challenging, especially in cases in which thyroid masses cannot be totally resected. It is important to choose the appropriate airway treatment modality. Currently, therapeutic rigid bronchoscopy procedures and endoluminal lasers, as well as airway stent insertion, are a management modality of near-total malignant airway obstruction. We report a rigid bronchoscopy procedure combined with laser and Y-stent silicone insertion in thyroid cancer with extension infiltration, as well as compression in the trachea covering the subglottic tracheal area up to the main carina and tracheo-bronchomalacia, manifesting as acute respiratory failure.

18 May 2023 in International Journal of Cancer Management
Verified
Journal Article
Open access
PDF file
MEMia Elhidsi
Mia Elhidsi
JZJamal Zaini
Jamal Zaini
DSDicky Soehardiman
Dicky Soehardiman
PPPrasenohadi Pradono
Prasenohadi Pradono
MRMenaldi Rasmin
Menaldi Rasmin
Context: The accuracy of narrow-band imaging (NBI) is a technology imaging for the assessment of lung cancer. Objectives: We aimed at summarizing the diagnostic profile of NBI for the early diagnosis of airway cancer lesions. Methods: We used PubMed, Scopus, and EMBASE databases to search for eligible studies published up to October 2022. Eligible studies have investigated the diagnostic profile of bronchoscopy NBI for the early diagnosis of lung cancer. The index test was NBI bronchoscopy, and the reference test was the histopathological results of lung cancer based on the World Health Organization (WHO) classification. In eligible studies, the detected lesions were confirmed by histopathology. We extracted true positive (TP), true negative (TN), false positive (FP), and false negative (FN) from the eligible studies to calculate the diagnostic profile of NBI. the quality assessment of diagnostic accuracy studies-2 (QUADAS-2) assessment was used as a tool to assess the risk of bias. A random-effects model was used to pool the summary receiver operating characteristic curve, specificity, and sensitivity. Results: Five studies were included, involving 1267 subjects with 1850 biopsy specimens. The overall pooled sensitivity and specificity for NBI bronchoscopy for the early detection of airway cancer lesions were 98% (95% confidence interval [CI]: 89% - 100%) and 77% (95% CI: 62% - 88%), respectively. All I2 values for sensitivity and specificity were 35.93% and 85%, respectively, with a P-value of 0.001. The positive LR was 4.35 (95% CI: 2.51 - 7.54, P < 0.001), and the negative LR was 0.03 (95% CI: 0.01 - 0.14, P = 0.006). The area under the receiver operating characteristic curve was 0.95 (95% CI: 0.92 - 0.96). Conclusions: Narrow-band imaging bronchoscopy can be used as a diagnostic modality for the early diagnosis of airway cancer lesions with good diagnostic accuracy.